Laboratory Corporation of America Holdings (LabCorp) has acquired Monogram pursuant to a cash tender offer followed by the merger of a wholly-owned subsidiary of LabCorp with and into Monogram.

As a result of the acquisition, Monogram became a wholly-owned subsidiary of LabCorp, and Monogram shares ceased to be traded on the Nasdaq global market at the close of trading on August 4, 2009.

At the effective time of the merger, all outstanding shares of Monogram common stock not validly tendered and accepted for payment in the tender offer were converted into the right to receive $4.55 per share in cash, without interest and subject to applicable withholding taxes. American Stock Transfer & Trust Company is acting as paying agent for the merger.

David King, chairman and CEO of LabCorp, said: "This acquisition is a significant step in the execution of LabCorp's strategy. By adding Monogram's innovative offerings to our extensive esoteric testing menu, we will advance our leadership in infectious disease and cancer testing, companion diagnostics and personalized medicine."

A service of YellowBrix, Inc.